Last reviewed · How we verify

Pulmonary actinomycosis — Treatment Landscape & Competitive Intelligence

Pulmonary actinomycosis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary actinomycosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Penicillin G Potassium In Plastic Container Benzylpenicillin Pfizer Penicillin-class Antibacterial 1947-01-01
penicillin penicillin Karlstad University Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Karlstad University · 1 drug in Pulmonary actinomycosis
  2. Pfizer · 1 drug in Pulmonary actinomycosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary actinomycosis:

Cite this brief

Drug Landscape (2026). Pulmonary actinomycosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-actinomycosis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing